The board of directors of SSY Group Limited announced that the Group has obtained the approval for drug production and registration for Ropivacaine Hydrochloride and Sodium Chloride Injection (100ml) from the National Medical Products Administration of China, being under type 4 chemical drug, regarded as passing the consistency evaluation and the third of such approval for the PRC entities. Ropivacaine Hydro chloride and Sodium Chloride injection is mainly used in local or regional anesthesia and acute pain management for surgery. This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.